Bifidobacterium and the gut-immune axis: Mechanistic insights and therapeutic potential.
Preclinical and clinical evidence suggests potential benefits in antibiotic-associated dysbiosis, inflammatory bowel disease, cancer therapy response, early life immune maturation, and selected metabolic and neuroimmune disorders, although the outcomes remain heterogeneous.